Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 3, 2002

View Archived Issues

Small-molecule dimerizer allows regulation of gene expression

The combination of squalamine and cisplatin inhibits ovarian cancer cell growth in nude mice

Vitex highlights safety and utility of Inactine in parasite eradication

NeuroSearch and Abbott extend research collaboration, select development candidate

Latest studies of immunosuppression with FK-778 discussed in Miami

New everolimus data presented at Miami transplantation meeting

APT-070 inhibits complement-mediated tissue damage and improves islet xenograft survival

Hepatic regeneration and graft survival improved with cytokine suppressor Ono-SM-362

Promising antiepileptic agent identified at Arzneimittelwerk Dresden/elbion

Heterocyclic compounds as selective COX-2 inhibitors presented in Barcelona

Structure of novel antipsychotic agent revealed by Lundbeck at scientific meeting

Reductions in liver lipid content on BMS-298585 in rodents fed high-fat diets

Different effects of thiazolidinediones on adipogenesis

Long-acting DAC:GLP-1 analogue effective and well tolerated in preclinical studies

Potential new agent for stress urinary incontinence in development at Roche Bioscience

NNC-25-2504: a glucagon antagonist that inhibits hepatic glucose production

sNDA filed for Lamictal for long-term management of bipolar I disorder

Debiopharm extends Eloxatin collaboration with Sanofi-Synthelabo

Enrollment under way for IL-13-PE38 in malignant glioma

Novuspharma and Micromet to codevelop MT-201 for cancer

Systemic ECE and NEP inhibition in humans treated with SLV-306

Excitatory amino acid receptor antagonists claimed for neurological disorders, etc.

Dopamine D1 receptor full agonists developed for treatment of Parkinson's disease

Endothelin receptor antagonists with utility in hypertension, ischemia, vasospasm, etc.

Pfizer and Abgenix disclose monoclonal antibodies that specifically bind to IGF-IR

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...